Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients

Journal of the American College of Cardiology

Volumn 65, Issue 2, 2015, Pages 125-132

  Golpanian, Samuel ^a   El Khorazaty, Jill ^b   Mendizabal, Adam ^b   DiFede, Darcy L ^a   Suncion, Viky Y ^a   Karantalis, Vasileios ^a   Fishman, Joel E ^a   Ghersin, Eduard ^a   Balkan, Wayne ^a   Hare, Joshua M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

Heart failure; Infarct size; Ischemic heart disease

Indexed keywords

6 MINUTE WALK DISTANCE; ABSOLUTE SCAR SIZE; ADULT; AGED; AGING; ANALYTICAL PARAMETERS; ARTICLE; CARDIAC IMAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE TEST; FEMALE; FUNCTIONAL STATUS; HEART INFARCTION SIZE; HUMAN; ISCHEMIC CARDIOMYOPATHY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL EXPANSION; THERAPY EFFECT; TREATMENT RESPONSE; AUTOTRANSPLANTATION; CELL CULTURE; CLINICAL TRIAL; CYTOLOGY; HEART VENTRICLE REMODELING; MESENCHYMAL STROMA CELL; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGING; CELLS, CULTURED; FEMALE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; QUALITY OF LIFE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84922611540     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.10.040     Document Type: Article

References (41)

1. Williams AR, Trachtenberg B, Velazquez DL, et al. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circ Res 2011; 108:792-6
2. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (PROCHYMAL) after acute myocardial infarction. J Am Coll Cardiol 2009;54:2277-86
3. Katritsis DG, Sotiropoulou PA, Karvouni E, et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005;65:321-9
4. Leistner DM, Fischer-Rasokat U, Honold J, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): Final 5-year results suggest longterm safety and efficacy. Clin Res Cardiol 2011; 100:925-34
5. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355:1210-21
6. de la Fuente LM, Stertzer SH, Argentieri J, et al. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an openlabel, nonrandomized, single-center pilot study (the TABMMI Study). Am Heart J 2007;154:79. e71-7
7. Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355:1222-32
8. Hendrikx M, Hensen K, Clijsters C, et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: Results from a randomized controlled clinical trial. Circulation 2006; 114 1 Suppl:I101-7
9. Zhuo Y, Li SH, Chen MS, et al. Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: Combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010;139:1286-94, 1294.e1281-2
10. Wright WE, Shay JW. Historical claims and current interpretations of replicative aging. Nat Biotechnol 2002;20:682-8
11. Blackburn EH. Switching and signaling at the telomere. Cell 2001;106:661-73
12. Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 2004;22:675-82
13. Mets T, Verdonk G. In vitro aging of human bone marrow derived stromal cells. Mech Ageing Dev 1981;16:81-9
14. D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 1999;14: 1115-22
15. Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: A simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999;107:275-81
16. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003;33:919-26
17. Dimmeler S, Vasa-Nicotera M. Aging of progenitor cells: Limitation for regenerative capacity? J Am Coll Cardiol 2003;42:2081-2
18. Rivard A, Fabre JE, Silver M, et al. Agedependent impairment of angiogenesis. Circulation 1999;99:111-20
19. Scheubel RJ, Zorn H, Silber RE, et al. Agedependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2003;42: 2073-80
20. Edelberg JM, Tang L, Hattori K, Lyden D, Rafii S. Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res 2002;90: E89-93
21. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003;108: 457-63
22. Kinkaid HY, Huang XP, Li RK, Weisel RD. What's new in cardiac cell therapy? Allogeneic bone marrow stromal cells as "universal donor cells". J Card Surg 2010;25:359-66
23. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005;433:760-4
24. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial. JAMA 2012; 307:1717-26
25. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med 2009;25: 563-77, 7.
26. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA 2014;311:62-73
27. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 2012;308:2369-79
28. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72
29. Lee J, Kook H, Chung I, et al. Telomere length changes in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 1999;24:411-5
30. Taraldsrud E, Grogaard HK, Solheim S, et al. Age and stress related phenotypical changes in bone marrow cd34+ cells. Scand J Clin Lab Invest 2009;69:79-84
31. Sugihara S, Yamamoto Y, Matsuura T, et al. Age-related BM-MNC dysfunction hampers neovascularization. Mech Ageing Dev 2007;128:511-6
32. Lewis NL, Mullaney M, Mangan KF, Klumpp T, Rogatko A, Broccoli D. Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients. Bone Marrow Transplant 2004;33:71-8
33. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 1996;110:325-32
34. Ingle L, Cleland JG, Clark AL. The long-term prognostic significance of 6-minute walk test distance in patients with chronic heart failure. Biomed Res Int 2014;2014:505969
35. Forman DE, Fleg JL, Kitzman DW, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol 2012;60:2653-61
36. Williams AR, Hare JM. Mesenchymal stem cells: Biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011;109:923-40
37. Middel B, Bouma J, de Jongste M, et al. Psychometric properties of the Minnesota Living With Heart Failure Questionnaire (MLHF-Q). Clin Rehabil 2001;15:489-500
38. Perin EC, Silva GV, Henry TD, et al. A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011;161: 1078-87.e3
39. Hong KU, Bolli R. Cardiac stem cell therapy for cardiac repair. Curr Treat Options Cardiovasc Med 2014;16:324
40. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006;367:113-21
41. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: Prospective cohort study. Heart 2008;94:730-6.